12.03.2024 • News

Kyowa Kirin to Build First US Pharma Operations

Japan-based pharmaceutical company Kyowa Kirin plans to build a $200 million biologics manufacturing center in Sanford, North Carolina, creating 102 jobs. This will be the company’s first North American pharmaceutical manufacturing operation, expected to create 102 jobs.

“Establishing a new center of excellence for biologics manufacturing in North America is a testament to the promising potential we see in our pipeline,” said Paul Testa, Kyowa Kirin’s executive vice president Supply Chain & Manufacturing, North America. “We believe the Sanford facility will become a vital part of our global manufacturing network – helping us train employees, deliver medicines with life-changing value, and support our future growth as a region and as a global business.”

The project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) awarded to Kyowa Kirin North America Manufacturing.

Kyowa Kirin expects to complete the project in four years.

© REB Images/Getty Images
© REB Images/Getty Images

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.